Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ · Manufacturing · Pharmaceutical preparations
$12.56+$0.0700 (+0.56%) on the dayAs of the close; data may be delayed.
CTNM price, last 12 months
Key stats
- Previous close
- $12.49
- Open
- $12.57
- Day range
- $12.10 – $12.88
- 52-week range
- $8.60 – $17.79
- Volume
- 404.9K
- Avg volume (20 days)
- 545.2K
- Market cap
- $472.5M
Performance
1W−7.2%
1M−26.2%
3M−11.5%
6M−8.0%
YTD+9.9%
1Y+19.6%
vs S&P 500, 1Y+2.8 pts
Technicals and fundamentals
About Contineum Therapeutics, Inc. Class A
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $472.5M